FDA clears Flow Neuroscience’s at-home depression treatment in US first

0268

The US Food and Drug Administration (FDA) has cleared Flow Neuroscience’s at-home, non-drug depression treatment, making it the first device of its kind to gain clearance from the agency.

The post FDA clears Flow Neuroscience’s at-home depression treatment in US first appeared first on Medical Device Network.

​Read More​ 

© 版权声明
文章版权归作者所有，只作为医疗器械技术同行的交流学习之用，未经允许请勿转载。
THE END
国际资讯官方抓取
喜欢就支持一下吧
点赞8 分享
相关推荐
FDA clears Bendit’s steerable vascular microcatheter-寰智汇
FDA clears Bendit’s steerable vascular microcatheter
FDA clears Bendit’s steerable vascular microcatheter
2025.12.13 27
Subsense secures $10m to advance BCI R&D efforts-寰智汇
Subsense secures $10m to advance BCI R&D efforts
Subsense secures $10m to advance BCI R&D efforts
2025.12.12 22
Vesalio secures FDA clearance for enVast clot retriever-寰智汇
Vesalio secures FDA clearance for enVast clot retriever
Vesalio secures FDA clearance for enVast clot retriever
2025.12.12 30
Guardant Health and Trial Library to expand access to US cancer trials-寰智汇
Guardant Health and Trial Library to expand access to US cancer trials
Guardant Health and Trial Library to expand access to US cancer trials
2025.12.12 32
FDA clears Flow Neuroscience’s at-home depression treatment in US first-寰智汇
FDA clears Flow Neuroscience’s at-home depression treatment in US first
FDA clears Flow Neuroscience’s at-home depression treatment in US first
2025.12.12 26
FDA greenlights Lumos Labs’ digital ADHD therapeutic-寰智汇
FDA greenlights Lumos Labs’ digital ADHD therapeutic
FDA greenlights Lumos Labs’ digital ADHD therapeutic
2025.12.11 41
评论 抢沙发

请登录后发表评论

    请登录后查看评论内容